Book Review:Childhood Leukemias

OncologyONCOLOGY Vol 14 No 3
Volume 14
Issue 3

Childhood Leukemias is a comprehensive text that encompasses every aspect of leukemia in children, ranging from general diagnosis, classification, and pathobiology to management and supportive care.

Childhood Leukemias is a comprehensive text that encompasses every aspect of leukemia in children, ranging from general diagnosis, classification, and pathobiology to management and supportive care. Edited by Ching-Hon Pui, MD, an experienced clinician and director of the Leukemia Division of St. Jude Children’s Research Hospital, the book boasts 43 expert contributors, many of whom are current or former members of the St. Jude faculty.

The handsome volume features clear, easy-to-read type and many high-quality illustrations, including comprehensive tables, diagrams, graphs, and 25 beautiful full-color plates. The chapters are all extensively referenced, most listing 200 to 300 citations each.

Although all of the chapters are of high quality, some deserve special mention. I enjoyed reading the personal historical perspective provided by Donald Pinkel at the beginning of the book. Dr. Pinkel was the first medical director of St. Jude Children’s Research Hospital and is credited with developing the curative approach to children with acute lymphoid leukemia, so-called total therapy, which incorporates effective presymptomatic treatment of the central nervous system. His review of “lessons learned” from the history of leukemia and the development of modern therapy is mandatory reading for any serious student of the subject.

The book contains many chapters reviewing areas of fundamental basic science that are relevant not just to leukemia but also to our general understanding of normal and neoplastic cell growth and differentiation. In-depth discussions of such topics as molecular genetics, cell biology, signal transduction, apoptosis, cellular immunotherapy, and gene transfer enrich the volume and provide a modern context. The association between translational science and leukemia is well covered in several chapters that review such topics as in vitro assays for drug sensitivity, detection of minimal residual leukemia, and applied pharmacokinetics.

Sections on the management of leukemia are logically organized and divided into chapters on acute lymphoblastic leukemia, B-cell acute lymphoblastic leukemia and Burkitt’s lymphoma, acute myeloid leukemia, myelodysplastic syndromes and chronic myeloproliferative disorders, and hematopoietic stem-cell transplantation. It would have been preferable if each of these treatment chapters had been organized along the same general outline; instead, the chapters vary in both organization and quality, with some of the topics (eg, epidemiology, cytogenetics, and immunophenotyping) duplicating material previously presented in other chapters. The chapter on hematopoietic stem-cell transplantation was disappointingly deficient in its discussion of alternative stem-cell sources and unrelated donor transplants. Cord blood transplants scarcely receive a mention.

Notwithstanding these shortcomings, however, this reference volume contains a wealth of information, essentially summarizing all that is known about childhood leukemias, beginning with the first description of leukemia by Virchow 150 years ago. While of great interest and most useful to pediatric hematologists and oncologists, this book would also be helpful to anyone in-terested in the biology or therapy of hematologic malignancies—for which childhood leukemias are the paradigm.

Articles in this issue

Comparative Economic Analysis of the Treatment of Relapsed Low-Grade B-Cell Non-Hodgkin’s Lymphoma (NHL) in France Using CHOP, Fludarabine, or Rituximab
FHIT Gene, Smoking, and Cervical Cancer
Final Report on the Safety and Efficacy of Retreatment With Rituximab for Patients With Non-Hodgkins Lymphoma
Prospective, Randomized, Controlled Study of Zevalin Radioimmunotherapy Compared to Rituximab Immunotherapy for B-Cell, Non-Hodgkins Lymphoma: Interim Results
IOM Medical Error Estimates Questioned, But Legislation Considered
Less Toxic Therapies for Hodgkin’s Disease May Reduce Secondary Cancers
Preserving Fertility in Young Women With Ovarian Cancer Does Not Decrease Survival
Iodine-131 Tositumomab for Patients With Transformed, Low-Grade Non-Hodgkin’s Lymphoma: Overall Clinical Trial Experience
Survival Rates Significantly Worse For African-Americans With Endometrial Cancer
Rituximab Has Significant Activity in Patients With Chronic Lymphocytic Leukemia
Responders to Rituximab Show Continued Tumor Regression Over Time and a Progression-Free Survival That Correlates With Response Classification
PhRMA Criticizes FDA’s Proposed Rule on Antibiotic Approvals
Phase II Study of Rituximab in Combination With CHOP in Patients With Previously Untreated Intermediate- or High-Grade Non-Hodgkin’s Lymphoma
New Antibiotic Effective in Treating Gram-Positive Bacteremia
Reduced-Dose Zevalin Radioimmunotherapy for Relapsed or Refractory B-Cell Non-Hodgkin’s Lymphoma Patients With Preexisting Thrombocytopenia: Report of Interim Results of a Phase II Trial
Related Videos
Experts on MM
Experts on multiple myeloma
Experts on MM
Daniel G. Stover, MD, suggests that stromal tumor infiltrating lymphocytes may serve as a biomarker of immune activation and can potentially help optimize therapy with microtubule-targeting agents for patients with metastatic breast cancer.
Experts on multiple myeloma
PRGN-3005 autologous UltraCAR-T cells appear well-tolerated and decreases tumor burden in a population of patients with advanced platinum-resistant ovarian cancer.
Related Content